Share your videos with the world

Sign Up | Log In | Help  

   
 
Related Tags: elekta  agility  mlc  radiation  therapy  innovation  cancer  treatments  oncology  technology  multivu  55638  progensa  pca3  assay  molecular  test  prostate  cancer  repeat  biopsies  genprobe  fda  healthcare  multivu  53530  baby  store  brands  products  mothers  expensive  spend  economy  fda  standards  savings  consumer  multivu  54418  children  sensorineural  hearing  loss  cord  blood  stem  cells  healthcare  multivu  53686  npwt  medical  technology  pico  single  use  negative  pressure  wound  therapy  smith  nephew  fda  patient  multivu  51011  bc  veritor  system  test  reader  flu  consumer  multivu  53615  promus  element  plus  stent  system  boston  scientific  fda  des  technology  coronary  artery  disease  ptcr  multivu  43510  cold  sore  abreva  herpes  fda  use  medicines  wisely  psa  medications  prescription  drugs  my  medicines  multivu  50878  food  safety  separate  cutting  boards  usda  prevent  food  poisoning  cdc  foodborne  illnesses  consumer  multivu  50582  dificid  fda  approval  drug  cdad  clostridium  treatment  disease  optimer  pharmaceuticals  health  healthcare  multivu  50177  phrma  women  health  medical  research  meds  medicine  diseases  depression  cancer  clinical  trials  fda  multivu  50270 
Search // fda
Results 73-82 of 82 for ' fda ' (0 seconds)
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it received 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S. Food and Drug Administration (FDA) for the BD Veritor™ System for rapid detection of Flu A+B. This is the first rapid influenza test system that incorporates a digital read out of results to receive CLIA waiver. To view Multimedia News Release, go to http://www.multivu.com/mnr/53615-bd-veritor-system-influenza-test-receives-510k-clearance-fda-clia-waiver
Tags // bc  veritor  system  test  reader  flu  consumer  multivu  53615 
Categories // Science and Technology 
Added: 4732 days ago by MultiVuVideos
Runtime: 0m54s | Views: 4854 | Comments: 0
Not yet rated
 

 

 

Boston Scientific Corporation (NYSE:BSX) announces U.S. Food and Drug Administration (FDA) approval for the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System, the Company’s next-generation drug-eluting stent (DES) technology. The PROMUS Element Stent, designed to provide physicians improved DES performance in treating patients with coronary artery disease, is built on an innovative platinum chromium (PtCr) platform with the market-leading everolimus drug. The Company plans to begin marketing the product in the U.S. immediately. To view Multimedia News Release, go to http://www.multivu.com/mnr/43510-boston-scientific-fda-promus-element-plus-platinum-chromium-stent-system
Categories // Science and Technology 
Added: 4754 days ago by MultiVuVideos
Runtime: 2m30s | Views: 5516 | Comments: 0
Not yet rated
 

 

 

Many cold sore sufferers try to tough out cold sores or try home remedies that can possibly make their cold sore even worse. There\'s a lot to be learned about the pesky cold sore that you may not know. For example, did you know that as temperatures drop and cold-weather-related illnesses rise, the chance of a cold sore being triggered increases? Cold temperatures and illness are just two triggers that can cause cold sore outbreaks. Other triggers include stress, sun exposure, injury to the mouth, and lack of sleep. Stress, which tends to rear its head during the winter months as many people prepare for the holidays, coupled with cold weather can create the perfect storm for a cold sore outbreak as we enter cold and flu season. Find out how FDA-approved Abreva allows you to win a speedy victory against cold sore attacks.
Tags // cold  sore  abreva  herpes 
Categories // People and Blog 
Added: 4762 days ago by a1broadcast
Runtime: 0m30s | Views: 4716 | Comments: 1
Not yet rated
 

 

 

The U.S. Food and Drug Administration (FDA) Office of Women’s Health today released a new public service announcement (PSA) titled, “Use Medicines Wisely,” to help raise awareness about safe medication use. Millions of people benefit from FDA approved medications and are living longer productive lives. However, when medications are used incorrectly, they can cause serious injuries, even death. Many of these injuries can be prevented. To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/fda/50878/
Added: 4810 days ago by MultiVuVideos
Runtime: 1m0s | Views: 5641 | Comments: 0
Not yet rated
 

 

 

The Ad Council is joining the U.S. Department of Agriculture’s Food Safety and Inspection Service, in partnership with the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC), to debut their first joint national multimedia public service campaign to help families prevent food poisoning in the home. The Food Safe Families campaign was announced this morning by USDA Secretary Tom Vilsack and HHS Secretary Kathleen Sebelius in time for the July 4th holiday and the start of summer when foodborne illnesses tend to increase—a time when many families celebrate with food. It’s also a time when foodborne illnesses tend to increase with more outdoor meals, and other factors that increase the risk for disease-causing bacteria in food. To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/adcouncil/50582/
Added: 4908 days ago by MultiVuVideos
Runtime: 0m31s | Views: 5890 | Comments: 0
Not yet rated
 

 

 

Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD. To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
Categories // News and Politics 
Added: 4939 days ago by MultiVuVideo
Runtime: 2m15s | Views: 7346 | Comments: 0
Not yet rated
 

 

 

Medical researchers are making unprecedented progress into understanding why women suffer disproportionately from a number of diseases. Those insights are providing information to help develop medicines to attack diseases such as osteoporosis, multiple sclerosis, depression, rheumatoid arthritis and age-related macular degeneration, all of which affect more women than men. To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/phrma/50270/
Categories // News and Politics 
Added: 4955 days ago by MultiVuVideo
Runtime: 1m56s | Views: 9904 | Comments: 0
Not yet rated
 

 

 

A small town lawyer is forced to fight a giant pharmaceutical company and the FDA to try to save his daughter’s life in Thompson’s edgy legal thriller. When his lawsuit uncovers fraud and corruption, he is confronted with an enemy who will resort to bribery, kidnapping and murder to win. Learn about the book and this author, www.larrydthompson.com Mystery Thriller
Categories // Miscellaneous  Business 
Added: 5028 days ago by cosproductions
Runtime: 1m22s | Views: 6423 | Comments: 2
Not yet rated
 

 

 

Allergan, Inc. (NYSE: AGN), the makers of LATISSE® (bimatoprost ophthalmic solution) 0.03%, announced today the launch of the LATISSE® Wishes Challenge campaign. Inspired by the tradition of blowing on an eyelash to make wishes come true, lifestyle designer Kathy Ireland, professional ballroom dancer Chelsie Hightower and style guide Bobbie Thomas will each lead teams of LATISSE® users from across the country who are challenged to raise more than a quarter of a million dollars for the Make-A-Wish Foundation, a nonprofit organization dedicated to granting the wishes of children with life-threatening medical conditions. LATISSE® solution is the first and only prescription treatment approved by the U.S. Food and Drug Administration (FDA) to grow lashes longer, fuller and darker for those with inadequate or not enough lashes (eyelash hypotrichosis). To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/latisse/43354/
Categories // News and Politics 
Added: 5285 days ago by MultiVuVideo
Runtime: 2m34s | Views: 8384 | Comments: 0
Not yet rated
 

 

 

California News on Ibogaine Treatment 20 Feb, 2004 - BAY AREA (KRON 4) - Drug addiction has been the plague of modern America. But that could now change forever. What started as a rumor may now actually be an incredible breakthrough in the battle against addictions of all kinds. Features Dr. Deborah Mash who says she is going to submit to FDA her data gathered in her St. Kitts clinic. Some addicts may have a long history of ADHD btw. The history of ADHD is often said to start with George Still 1902. Actually it starts already 1798 with George Crichton: http://adhd-npf.com/adhd-history/
Added: 6378 days ago by CocaCola Jesus
Runtime: 9m21s | Views: 11503 | Comments: 1
     
 

 

 

Page 7 of 7  |  Go to page     |  ««FIRST «Previous  



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2024 ClipMoon.com. All rights reserved.